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Sarcoidosis has been recognized as a disease with 
immunologic features for almost 60 years [1], and 
yet, the exact nature of immunologic malfunction 
remains controversial [2-4]. Certain features can 
be considered firm: the disease is manifested by 
widespread granulomata involving lymphoid and 
diverse other tissues . Indeed, it is rarely necessary 
to be very precise in the choice of biopsy material. 
Almost any lymph node, even if it appears normal , 
is likely to contain characteristic non caseating 
granulomata. Depression of skin reactivity to anti-
gens which have been known to produce delayed 
hypersensitive reactions in normal persons is not a 
universal feature of the disease , but in the vast 
majority of published series , the patient popula-
tion demonstrates skin anergy to sume degree . 
Paradoxically, a granulomatous response to 
K veim antigen is often observed [5] ; however, the 
time course and histologic characteristics make it 
difficult to classify this reaction with other 
delayed-type hypersensitivity reactions [6]. Less 
constant are reports concerning the reduced num-
ber [7] and function [8,9] of T-lymphocytes , and 
macrophages [10], a deficiency of which singly or 
in combination could account for the observed 
anergy. Variations in the staging of the disease, 
and the frequent failure to assess the effect of 
steroid treatment may contribute to this variabil-
ity. 
In an effort to study the immunologic function of 
patients with sarcoidosis , we have divided them 
into two groups: those receiving and those not 
receiving steroids. The disease was staged accord-
ing to chest x-ray findings. Clinical symptoms and 
signs as well as various laboratory tests were used 
to define disease activity. Cutaneous delayed hy-
persensitivity responses to five common antigens 
were measured and compared to results from in 
vitro tests for immunologic competence. Peripheral 
blood T - and B-Iymphocytes were counted and 
responses to mitogen and to antigens were mea-
sured. Because earlier results from our laboratory 
[11] suggested the presence of an immunologic 
suppressor, we investigated and now report the 
return of depressed lymphocyte function towards 
normal after a period of cell culture in vitro. In this 
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paper, we shall speculate on the cause of the 
immunologic dysfunction in sarcoidosis with a 
particular effort to reconcile apparently disparate 
findings. 
MATERIALS AND METHODS 
Patients 
Thirty-four patients with sarcoidosis were studied. 
Twelve were being treated with steroids at the time of 
study, and the remaining 22 had never received steroid 
medication. Half of the patients were male and their ages 
ranged from 24 to 52 years. Ten white, and 24 black 
patients comprised the study group. Entry was defined 
by typical signs and symptoms, a positive response to 
K veim antigen, and the presence of granulomata in 
biopsy material obtained from lymph node. 
Skin Tests for Cutaneous Delayed Hypersensitivity 
All subjects were tested prior to in vitro studies by 
intradermal injection of 0.1 ml of the following antigens: 
PPD (Connaught Laboratories, Toronto, 5 TU); a 1:100 
dil ution of Candida albicans (Hollister-Stier, Yeadon, 
Pennsylvania); a 1: 100 dilution of trichophyton (Hollis-
ter-Stier); mumps skin test antigen (Eli Lilly, Indianapo-
lis, Indiana); and streptokinase (50 units)-streptodornase 
(12.5 units) (SKSD-Elkins Sinn, Cherry Hill , New 
Jersey) . Reactions were read at 48 hr and a response of 10 
mm of induration was considered positive. 
Enumeration of T- and B-Lymphacytes 
B-lymphocytes were identified by the presence on their 
surface of readily identified immunoglobulin; the capac-
ity of some lymphocytes to form rosettes spontaneously 
by binding sheep red blood cells to their surface was used 
as a marker for T -cells. Both methods are detailed in a 
previous publication [12]. 
Stimulation of Lymphocytes to Synthesize DNA 
Mononuclear leukocytes were separated from whole 
blood anticoagulated with heparin (20 U/mI) by sedimen-
tation on Ficoll-Hypaque gradients. Cells were stimu-
lated by either phytohemagglutinin (PHA), C. albicans 
antigen (Hollister-Stier) , or by pooled irradiated 
allogeneic lymphocytes obtained from 4 donors with 
mixed lymphocyte reactions (MLR). Details of the lym-
phocyte studies have been previously reported [12]. 
RESULTS 
Skin Tests 
The results of skin testing are summarized in 
Table 1. Anergy was observed in both the steroid 
and untreated groups when they were compared to 
control patients. Two points should be stressed: (a) 
fewer untreated sarcoid patients reacted to any 
antigen and those who did react manifested 
smaller reactions than controls; and (b) those 
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TABLE 1. Delayed cutaneous hypersensitivity in tested subjectsa 
Subjects No. tested Candida 
Controls 10 29.7 (100) 
Sarcoid" and no prednisone 18 8.6 (50) 
Sarcoid and prednisone 11 27 (27) 
a Reprinted with permission from [12] 
b Percentage responding in parentheses 
sarcoid patients treated with steroids who reacted, 
did so with normal-size reactions suggesting that, 
in certain patients capable of limited cutaneous 
reactivity, steroids may paradoxically potentiate 
this reactivity. 
Enumeration of T- and B-Lymphocytes (Table II) 
No alteration in the number of circulating 
immunoglobulin-bearing cells (B-cells) was noted 
in either group. Three patients in the untreated 
group had low numbers of circulating T-cells (35, 
41,41 %), but there was no significant reduction in 
the group as a whole. The mean figure for T-Iym-
phocytes in the steroid-treated group was signifi-
cantly low due principally to 5 individuals with 
counts 2 SD below the mean normal value. No 
compensatory increase in B-cells in these patients 
was noted; a larger proportion of null cells 
appeared. The observed reduction in numbers of 
T -cells alone could not account for the immuno-
logic unresponsiveness. 
In vitro stimulation with PHA, Candida and by 
MLR 
Results of lymphocyte stimulation tests are 
shown in Figure 1. The bottom of each bar repre-
sents the incorporation of [3H ]thymidine (counts 
per minute, cpm) by unstimulated culture after 3 
days of incubation in the case of PHA, and after 7 
days of culture for Candida and MLR. The top of 
each bar represents the incorporation of [3H ]thy-
midine in stimulated cultures. Since the ordinate 
is drawn to a log scale, the stimulation index 
cpm stimulated culture 
cpm unstimulated culture 
is represented by the length of the bar; thus the 
baseline, the absolute level of stimulation, and the 
ratio may be seen in the same figure. 
Stimulation by PHA (left side of Fig. 1) was as 
effective in the untreated sarcoid patients as in the 
controls. Prednisone-treated patients had a higher 
mean baseline and a lower peak level of response 
than did controls. This reduction in responsiveness 
was significant (p < 0.05). Lymphocyte stimula-
t ion with pooled homologous lymphocytes demon-
strated significant impairment of response in both 
sarcoid groups, and baseline counts in both groups 
were elevated. Similar results were produced by 
stimulation with Candida antigen although the 
Mean diameter of induration b (mm) 
PPD Trichophyton SK-SD Mumps 
12 (20) 15(90) 21(90) 20(100) 
9.5(5.5) 9(22) 20(22) 9(22) 
33 (9) 15(18) 10(18) 9(27) 
large variance in response of untreated patients did 
not permit a conclusion of significant reduction in 
response. 
In normal subjects, excellent correlation was 
obtained between skin test reactivity and in vitro 
responses; the coefficient of determination (r2) was 
0.56 and the coefficient of correlation (r) was 0.8 
where 1.0 would be perfect correlation. No correla-
tion in sarcoid patients between skin tests and in 
vitro responses was obtained (Fig . 2); the coeffi-
cient of determination was 0.04 and the coefficient 
of correlation was 0.2. 
The disparity between the skin test in vivo, and 
the lymphocyte stimulation tests in vitro led us to 
search for serum inhibitory factors which would 
suppress lymphocyte and/or macrophage activity 
in vivo but would be removed during the prepara-
tion of the cells for in vitro tests. 
It is difficult to compare individual samples of 
serum or plasma with respect to their ability to 
support lymphocyte stimulation of normal homolo-
gous lymphocytes . There is so great a variation in 
normal samples that a significant abnormality of 
other than huge proportions would be missed. This 
fact is easily seen in Figure 3. Lymphocytes from a 
normal individual were cultured with 25 individual 
homologous plasma samples at a concentration of 
15% and stimulated by PHA. The results were 
compared with responses of the same lymphocytes 
in 25 different pools of plasma. Each pool consisted 
of 3 individuals randomly selected. While the 
mean response of the lymphocytes cultured in 
individual plasma samples was the same as that 
from cells cultured in pooled plasma, the variance 
of the second group was markedly reduced . It can 
be inferred (erroneously) from these data that 7 of 
25 normal plasma samples would have supported 
lymphocyte stimulation subnormally if compared 
to a normal pool of plasma (p < 0.05). We 
therefore chose to compare the individual's own 
leukocyte response in autologous plasma (A) with 
TABLE II. Enumeration of B-cells and T-cells in patients 
with sarcoid 
Subjects (No.) " B" cells "T" cells (% ± SE) (% ± SE) 
Controls (54) 26 ± l.5 60 ± l.5 
Sarcoid-no steroid Rx (22) 25 ± l.6 59 ± 4.3 
Sarcoid-steroid Rx (18) 27 ± 7.0 47 ± 4.0 
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FIG. l. Lymphocyte stimulation of patients with PHA, Candida, and allogeneic lymphocytes (MLR). 0 = Control 
patients; ~ = untreated sarcoid patients; lSI = steroid-treated sarcoid patients . Numbers of patients are given in 
parentheses . Upper limit of each bar represents cpm of stimulated cultures ; lower limit of bar shows cpm of 
unstimulated cultures ± SEM. 
the response in a homologous pool of normal 
plasma (B) as a ratio A/B. Almost invariably this 
ratio was 1.0 or higher, because individual leuko-
cytes were stimulated as well or better in their own 
plasma as in a pool of homologous plasma. This 
finding is shown in Figure 4, where the response to 
Candida (a) and to PHA (b) of leukocytes from 
normal patients and patients with sarcoidosis are 
plotted as the ratio of the response in autologous 
plasma divided by the response in pooled homolo-
gous plasma. Twenty-nine sarcoid patients were 
studied: the responses of 13 of the 29 and 1 of 20 
normals were significantly less (p < 0.05) in 
cultures containing autologous plasma. 
Such decreased responses could be due either to 
a deficiency in sarcoid plasma or to an inhibitor. 
Studies reported elsewhere [11] have demonstrated 
the presence of suppressive activity in about Y3 of 
the sarcoid plasmas studied, but it should be noted 
that the degree of supression was modest and there 
was no direct correlation between the presence of 
inhibitors and either disease activity or cutaneous 
anergy. One possibility for the lack of correlation 
between skin tests and in vitro lymphocyte studies 
was the removal of suppressed cells from the 
suppressive environment, permitting "recovery" of 
responsiveness. To test this hypothesis we studied 
sarcoid patients whose leukocytes demonstrated 
increased spontaneous incorporation of [3H]thymi-
dine and decreased responsiveness to Candida or to 
homologous leukocytes. Fresh leukocytes were 
obtained from these patients and "precultured" for 
4 days in pooled normal human plasma. At day 4, 
Candida antigen or pooled homologous, irradiated 
leukocytes were added; after an additional 7-day 
culture period the cells were pulsed with [3H]thy-
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midine and counted. The results of stimulation of 
the same leukocytes begun on day 0 or day 4 are 
shown in Figure 5. Control leukocytes had a small 
decrease in baseline incorporation and a slight 
decrease in total counts after preculture, suggest-
ing a decrease in precursor or stimulatable cells 
during the 4-day period. The patients' cells demon-
strated a fall in baseline incorporation, but also a 
rise in total counts after stimulation-both tending 
towards the normal condition. These findings are 
preliminary because of the small numbers of 
patients studied, but they support the notion of in 
vivo suppression with in vitro escape. 
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FIG. 4. The response (a) to Candida albicans and (b) 
to PHA of lymphocytes cultured with autologous plasma 
divided by the response of the same lymphocytes cul-
tured in pooled homologous plasma. 0 = Normal sub-
jects; /::,. = untreated sarcoid patients; • = treated 
sarcoid patients. (Reprinted with permission from (111) 
DISCUSSION 
The data presented here are consistent with the 
view that anergy in sarcoid is not due to a 
deficiency but rather an active suppression. The 
cells to be considered are responding T -lym-
phocytes, macrophages, and a putative population 
of suppressor cells. Whether suppressor cells are a 
separate subset of T -lymphocytes as is the case in 
the mouse [13] or are responding T -cells whose 
product(s) acts as a negative feedback inhibitor is 
not known. The cell(s) acted upon is also unknown 
and both the macrophage and lymphocyte remain 
possibilites. There are several observations which 
need to be reconciled to this etiology of sarcoid: (1) 
Improvement in skin reactivity has been reported 
following local or systemic treatment with steroids 
[10,14,15]. Indeed, in our series those steroid-
treated patients who did react produced reactions 
comparable in size to controls. A differential cellu-
lar effect of steroids is well known [16] and may be 
invoked to explain the "paradoxical" effect of 
steroids in sarcoid. (2) The poor correlation 
between in vivo and in vitro responsiveness may be 
explained by the recovery of suppressed cells when 
removed from the suppressive environment as 
demonstrated previously. (3) Anergy is relative 
and can be overcome by strong antigenic challenge. 
It has been amply shown that patients with sar-
coidosis who develop tuberculosis usually develop 
positive cutaneous reactivity [17,18]. Skin tests 
performed with emulsified tuberculin yielded an 
increased number of positive reactions among 
subjects with sarcoid but not among a control 
population [19]. Patients with sarcoid who were 
immunized with BCG reacted when tested with 
100 to 250 tuberculin units (TU) but remained 
anergic to 5 TU [20]. These data suggest that 
suppression is antigen dependent and point to an 
immune complex as an attractive possible suppres-
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sor. (4) The fact that passively acquired delayed 
hypersensitivity is rapidly lost in sarcoid patients 
[21] is further evidence of active suppression of the 
sarcoid environment. (5) Secondary effects of sar-
coid anergy are rarely observed. Patients do not 
develop viral or fungal infection with great fre-
quency [5] in sharp contrast to the anergy of 
Hodgkin's disease. This finding is probably a 
corollary of (3) above, again suggesting a dynamic 
reversible process possibly dependent upon antigen 
concentration. (6) The presence of circulating 
lymphokines in sarcoid and the reported dissocia-
tion between lymphokine production and cellular 
proliferation are both likely to represent the vec-
tors of stimulation by antigen on the one hand, and 
suppression on the other. 
The foregoing does not readily distinguish 
between macrophages or lymphocytes as the sup-
pressed cells. Some experiments suggest a macro-
phage defect: when supernatants of concanavalin 
A-stimulated lymphocytes were injected into sar-
coid patients, the response was reduced compared 
to controls [10]. The time course of the reaction 
was faster than a normal delayed hypersensitivity 
reaction, reaching a peak in 6 hr. Thus, the 
lymphokine released by concanavalin A may ac-
tually be producing a cutaneous basophil reaction 
(Jones-Mote) rather than a typical delayed type 
reaction, and the events leading to basophil chemo-
taxis are blocked in sarcoid. This idea can easily 
be checked by appropriate histologic stains of the 
skin biopsy material. 
The data presented in this communication sug-
gesting recovery of suppressed responses of sarcoid 
leukocytes by preculture in vitro are similar to 
those recently reported in patients with fungal in-
fections and suppressed cellular immunity [22]. 
This technique will, if confirmed in a greater num-
ber of patients, permit separation and recombina-
tion of fresh and cultured macrophages and lym-
phocytes. Such recombinants may more clearly 
define the suppressed cell type in sarcoidosis. 
SUMMARY 
Patients with sarcoidosis were separated into 
those treated or not treated with prednisone. Skin 
test reactivity of both groups was clearly dimin-
ished but a significant decrease in T -cells was seen 
only in the steroid-treated group and this was not 
sufficient to explain the profound anergy. Lym-
phocyte stimulation studies generally revealed ele-
vated baseline incorporation of [3H ]thymidine and 
reduced stimulation. Factors were present in the 
plasmas of 1/4 to V3 of the patients which sup-
pressed normal lymphocyte stimulation. When 
cells from 3 sarcoid patients were precultured in 
Sept. 1976 
vitro, recovery towards normal occurred with a 
drop of the elevated baseline and rise in peak 
response. 
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DISCUSSION 
Kirkpatrick: Dr. Kantor, for years I have heard that 
the anergy in sarcoidosis was due to rapid clearing of the 
test antigen from the skin . These studies were reportedly 
done with labeled antigen. When the antigen was sus-
pended in cortisone acetate, clearance was delayed and 
the test was positive. Have you examined this question? 
Secondly, in your precultured cells have you had an 
opportunity to look at dose-response curves? They might 
reflect a change in suppressive activity . 
Kantor: Antigen is not cleared faster in steroid treated 
patients, so I don't believe retention is the basis of the 
steroid effect in sarcoid. We have not yet studied time-
dose relationships in the proliferative responses of 
precultured cells. There may well be different peaks in 
these parameters. 
Franklin: The paradoxical effect of steroids is not 
unique to sarcoid, since we have observed the same 
phenomenon in systemic lupus erythematosus where skin 
tests appear with the start of steroid therapy in previ-
ously anergic subjects. 
Is the "cure" of the proliferative response after in vitro 
culture unique to sarcoid or is it seen also in other 
diseases with an impaired in vitro response? 
Kantor: I am not familiar with attempts to pre culture 
cells from patients with lupus who demonstrate anergy. 
3tobo has reported [Stobo S, et aI, Clin Res 23:289A, 
L975] that he had pre cultured cells of patients with 
fungal diseases or anergy for 7 days and showed return of 
fUnction. He was also able to suppress recove~ed cells by 
adding fresh cells from the patient. 
Rocklin: I would like to make two points. First, I think 
that the apparent dissociation between skin reactivity 
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and in vitro lymphocyte proliferation in responses in pa-
tients with sarcoidosis reflects the choice of in vitro assay 
employed. While lymphocyte proliferation was originally 
shown to correlate closely with in vivo delayed hypersen-
sitivity of the normal host, it has become apparent with 
more extensive use of this technique that there are many 
exceptions. On the other hand, MIF production has been 
found to mirror more closely the skin reactivity of the 
same normal subjects. In our studies in some 50 patients 
with sarcoidosis , we found that proliferative responses to 
mitogens and antigens in anergic patients were normal in 
about 50% of cases, while MIF production to the same 
antigens was absent in all. These findings suggested a 
partial defect in lymphocyte function in some anergic 
patients, limited to the mediator-producing population. 
Secondly, there may not be a defect at all in cellular 
immune function. Since we measure lymphocyte func-
tion by sampling peripheral blood cells, it is possible that 
our negative responses really reflect an absence of antigen 
reactive cells from this pool but their presence might be 
detected if we could sample tissue or control lymphoid 
cells. In other words, there can be a change in the 
circulatory patterns of lymphoid cells and we have a 
sampling error. 
Kantor: I am fascinated by the dissociation which you 
described. Since the MIF assay you used required guinea-
pig macrophages, it raises the question again of macro-
phage competence. The change in migratory patterns 
may well be important in providing the particular cells in 
peripheral blood which we test. Unfortunately , in man, 
blood is the only practical lymphoid tissue to study. 
Claman: First, we recognize that suppressive factors 
may be important, but you showed serum suppressive 
factors in only VI of your sarcoid patients. Second, the 
presentation of complete mitogen data on a log scale is a 
good idea. It does , however, magnify the lower end of the 
scale. Those increases in baseline [3H ]thymidine incorpo-
ration by unstimulated sarcoid cells are really very small 
in terms of cpm . In spite of this , I believe that such 
increased " baselines" may be very important. Now a cell 
may be doing things furiously without having increased 
DNA synthesis. It might be a good idea to look at RNA 
synthesis by uridine incorporation . 
Kantor: We found weak inhibitors of DNA synthesis 
in about 13 of our patients . I am not too disturbed by this 
because serum may not be the best place to look for 
inhibitors. I agree that the log scale magnifies the 
differences at the low end of the scale but our means of 
presentation show all the data-unstimulated, stimu-
lated, and index-which permits the observer to draw his 
own conclusions . 
Krueger: I would like to propose another theory to 
explain anergy in the diseases discussed this morning, i.e., 
secondary syphilis, lepromatous leprosy, disseminated 
leishmaniasis, sarcoidosis, and possibly schistosomia-
sis. Basically one notes in all of these diseases activated 
or well differentiated macrophages, i.e., macrophages 
engulfing organisms or forming granulomas. This should 
make us inquire as to the possibility that these activated 
macrophages are releasing an inhibitor of cell-mediated 
immunity. Indeed we have learned from Dr. Warren that 
granulomas release inhibitors of DNA uptake by stimu-
lated lymphocytes. Further there are reports which 
suggest that products of activated macrophages inhibit 
lymphokine production in response to excess antigen, by 
lack of proper recognition or through some other abnor-
mality. These events may lead to excess macrophage 
activation and production of inhibitors that inhibit the 
ability of the lymphocytes to react to skin test antigens 
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through lymphokine amplification. Such a possibility 
would explain the presence of inhibitors in sera seen by 
Dr . Kantor and the lack of carcinoma, fungal diseases, 
and the like in subjects with these diseases. That is to 
say, the activated macrophages can handle these abnor-
malities as they develop. It would also explain the steroid 
response in sarcoid in that steroids will prevent lympho-
kines from acting on macrophages, ergo no macrophage 
inhibitor release. As a matter of fact, I believe such a 
theory would explain all of the anergic problems outlined 
by Dr. Kantor. 
Kantor: The macrophage needs to be studied in this 
regard. One of the exciting aspects of this ability to 
preculture cells and have them return towards normal is 
the possibility of separating lymphocytes and macro-
phages to assess their competence separately. 
Warren: The immunologic responses seen in human 
sarcoidosis in which high immunoglobulin levels and lack 
of responsiveness to both specific antigens and mitogens 
in the presence of granuloma formation may be explaina-
ble by new knowledge of immunoregulation. Thus, the 
immunologic manifestations of sarcoidosis which could 
be assumed to be related to the immunologic responses to 
Vol. 67, No.3 
whatever antigens are responsible for sarcoid, might, 
indeed, be largely the immunoregulatory systems sup-
pre~sing the responses to the antigen (i.e., the sarcoid 
grap.uloma) . 
Kantor: I agree with you that the disease is the visible 
resultant of concurrent response and suppression. For 
purposes of study one focuses on one or the other, but 
both are operative. 
Franklin: I want to come back to Dr. Warren's 
comment on the concept and importance of 
immunoregulation and consider, perhaps somewhat spe-
culatively-the nature of amyloidosis as possibly a result 
of the over-expression of such a regulatory response. The 
recent observation by Cathcart's group that SAA can 
inhibit in vitro the antibody response in the Mishell-Dut-
ton system, and the occurrence of amyloidosis and 
elevated SAA levels in a variety of states of strong 
antigenic stimulators, might perhaps lead us to consider 
the possibility that amyloidosis is a result of an over-
response of such an immunoregulatory response-per-
haps by suppressor cells. This is a possibility that we can 
now investigate directly. 
